ArticleFrontiers in oncology2026
Complete metabolic response in stage IV Merkel cell carcinoma after combined avelumab and radiotherapy: a case report suggestive of an abscopal effect.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with limited therapeutic options once it reaches metastatic stages. While immune checkpoint inhibitors like avelumab have improved outcomes, achieving a complete and durable response in stage IV disease remains challenging. We report the case of a 75-year-old male diagnosed with stage IV MCC, negative for Merkel cell polyomavirus (MCPyV) and with 1% PD-L1 tumor cell expression, presenting with a primary tumor in the right thigh, a regional inguinal nodal conglomerate, and a distant mediastinal lymph node metastasis. Initial treatment with first-line avelumab resulted in a discordant response, with a near-complete metabolic response of the mediastinal lesion but persistence of the primary tumor. Localized radiotherapy (RT) - 66 Gy in 33 fractions delivered by intensity-modulated radiotherapy (IMRT), encompassing the primary tumor, the inguinal nodal conglomerate, and at-risk regional nodal basins - was subsequently added while avelumab was continued. Following completion of RT and the fourteenth cycle of avelumab, a complete metabolic and morphological response was documented by FDG PET-CT across all disease sites, including the non-irradiated mediastinal node, consistent with an abscopal effect. Treatment was reasonably well tolerated, with grade 3 radiodermatitis and grade 1 radiation cystitis as the only reported adverse events, and no immune-related toxicity. The patient has since maintained a durable remission under surveillance with maintenance RT. This case suggests a potent synergistic interaction between avelumab and RT, potentially mediated by an abscopal effect at the non-irradiated distant site. The strategic combination of these therapies may overcome initial resistance to immunotherapy in advanced MCC, highlighting the need for further clinical investigation into radio-immunotherapy protocols for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.